Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK‐positive non‐small‐cell lung cancer: Case report and review of the literature

Non‐small cell lung cancer patients with anaplastic lymphoma kinase or c‐ros oncogene 1 mutations who are treated with the tyrosine kinase inhibitor crizotinib rarely develop crizotinib‐associated renal cysts (CARCs). Here, we present a case report and review of the literature supporting the hypothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiest, Nathaniel E., Tzou, Katherine S., Olson, Matthew T., Herchko, Steven M., Bajalia, Essa M., Thiel, David D., Lou, Yanyan, Zhao, Yujie, Manochakian, Rami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190584/
https://www.ncbi.nlm.nih.gov/pubmed/34136235
http://dx.doi.org/10.1002/ccr3.4278
Descripción
Sumario:Non‐small cell lung cancer patients with anaplastic lymphoma kinase or c‐ros oncogene 1 mutations who are treated with the tyrosine kinase inhibitor crizotinib rarely develop crizotinib‐associated renal cysts (CARCs). Here, we present a case report and review of the literature supporting the hypothesis that CARCs may correlate positively with progression‐free survival.

Ejemplares similares